COL5A2 was reported to be highly expressed in metastatic osteosarcoma, and silencing COL5A2 impaired cell invasion and metastasis by inhibiting the TGF-β and Wnt/β-catenin signaling pathways (Han et al., 2022). Here, COL5A2 is linked to osteosarcoma.